Menlo Therapeutics Inc.

Menlo Therapeutics Inc We are a late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1R, given as a once daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms.

Bank Name Menlo Therapeutics Inc.
Stock Exchange NASDAQ
Symbol MNLO
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Mr. Steven L. Basta
Employees 36
Registered Year 2011